Mucosal Vaccines
- 1st Edition - October 14, 1996
- Latest edition
- Author: Hiroshi Kiyono
- Editors: Hiroshi Kiyono, Pearay L. Ogra, Jerry R. McGhee
- Language: English
This comprehensive, authoritative treatise covers all aspects of mucosal vaccines including their development, mechanisms of action, molecular/cellular aspects, and practical… Read more
- Provides the latest views on mucosal vaccines
- Applies basic principles to the development of new vaccines
- Links basic, clinical, and practical aspects of mucosal vaccines to different infectious diseases
- Unique and user-friendly organization
"This book contains several chapters providing a good overall view of the cellular structure and function of the mucosal immune system. The remaining chapters provide a good, broad foundation for understanding the current problems in vaccine research as well as a detailed description of cutting edge research on vaccines against specific mucosal pathogens and vaccines designed to protect specific mucosal sites. The editors have therefore succeeded in summarizing current views and concepts relating to new generations of vaccines and vaccine technologies." —DOODY'S
"In the preface to this book, the editors state that "Mucosal Vaccines summarizes the most current and updated views and concepts related to the development of new generations of vaccines.' This tall order is beautifully delivered in 33 chapters and almost 500 pages by contributing authors, all respected experts in their fields...The editors have done an excellent job of putting together the many chapters in logical and understandable groupings, and the authors should be cited for their excellent contributions."—ASM NEWS
- Edition: 1
- Latest edition
- Published: October 14, 1996
- Language: English
HK
Hiroshi Kiyono
Since the 1970s, Professor Kiyono has been investigating and characterizing unique features of the mucosal immune system to establish mucosal immunology as an area of the immunology field as well as to develop effective and safe mucosal vaccines against infectious diseases and mucosal immune therapies against allergic and inflammatory diseases. He recently developed cold-chain- and needle-free rice-based vaccines (MucoRice) with the cooperation of agricultural researchers. The vaccine antigens exogenously expressed in MucoRice are temperature-stable for at least 2.5 years and are resistant to digestive enzymes, thus they effectively induce vaccine antigen-specific protective immunity in both systemic and mucosal compartments against toxins produced by pathogenic microorganisms (e.g., cholera toxins). Additionally, his efforts aim to clarify the immunological cross-talk between the mucosal immune system and mucosal environmental factors (e.g., commensal bacteria and dietary materials) in immunological homeostasis. These studies will lead to the development of novel immune therapies against mucosal immune diseases, such as food allergy, rhinitis, and inflammatory bowel diseases.
PO
Pearay L. Ogra
JM
Jerry R. McGhee
HK
Hiroshi Kiyono
Since the 1970s, Professor Kiyono has been investigating and characterizing unique features of the mucosal immune system to establish mucosal immunology as an area of the immunology field as well as to develop effective and safe mucosal vaccines against infectious diseases and mucosal immune therapies against allergic and inflammatory diseases. He recently developed cold-chain- and needle-free rice-based vaccines (MucoRice) with the cooperation of agricultural researchers. The vaccine antigens exogenously expressed in MucoRice are temperature-stable for at least 2.5 years and are resistant to digestive enzymes, thus they effectively induce vaccine antigen-specific protective immunity in both systemic and mucosal compartments against toxins produced by pathogenic microorganisms (e.g., cholera toxins). Additionally, his efforts aim to clarify the immunological cross-talk between the mucosal immune system and mucosal environmental factors (e.g., commensal bacteria and dietary materials) in immunological homeostasis. These studies will lead to the development of novel immune therapies against mucosal immune diseases, such as food allergy, rhinitis, and inflammatory bowel diseases.